engleski

Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children

Aims were to assess: the effects of prophylaxis with RSV monoclonal antibody compared with placebo, no prophylaxis or another type of prophylaxis for reducing the risk of hospitalization due to RSV infection in high- risk infants and children ; the effects of prophylaxis with RSV monoclonal antibody as assessed by the use of resources, compared with placebo, no prophylaxis or another type of prophylaxis ; the incremental costs associated with changes in resource use in patients receiving RSV monoclonal antibody prophylactically, compared with placebo, no prophylaxis or another type of prophylaxis.

palivizumab; monoclonal antibody; RSV; infection; children

nije evidentirano